Cabotegravir Pellet Implant with Levonorgestrel
The cabotegravir pellet implant with levonorgestrel is a long-acting multipurpose prevention technology implantable product developed by CONRAD combining cabotegravir, for HIV prevention, and levonorgestrel, for contraception, in a biodegradable subdermal pellet system. This product is a low-cost, biodegradable subdermal pellet-type implant system that provides tightly controlled, long-acting sustained release of its payload, is highly tunable, and does not require surgical removal.
*Also referred to as a dual-prevention product by MATRIX
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Systemic - Implant (Subcutaneous)
Mechanism of Action:
Integrase strand-transfer inhibitor; progestrin
Developer:
- CONRAD
Funding:
- Eastern Virginia Medical School
- U.S. Agency for International Development (USAID)
Funding Mechanism:
MATRIX
Active Ingredient(s):
- Cabotegravir
- Levonorgestrel
Product Indication(s):
- HIV
- Pregnancy
Useful Links: